The drug widely considered to be Amgen Inc.'s future growth driver won its first approval Friday, picking up a European nod in osteoporosis, even as analysts and investors await the expected FDA approval in July as well as detailed data in oncology settings slated for presentation at the upcoming American Society of Clinical Oncology meeting. (BioWorld Today) Read More
